Clinical Trials open to enrollment

ELVN-002-003 – “A Phase 1a/1b Study of ELVN-002 Combined with Trastuzumab in Advanced Stage HER2+ Solid tumors, and ELVN-002 Combined with Trastuzumab and Chemotherapy in Advanced Stage HER2+ Breast Cancer or Colorectal Cancer”

Catanzaro – AOU Renato Dulbecco – Presidio Mater Domini
Principal Investigator: Prof. Pierfrancesco Tassone
For information about enrollment, contact: clinicaltrials.oncology@unicz.it (Tel: +39 0961-3647921)

 

CAMBRIA-1 – “A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy”

This study investigates the potential role of camizestrant, a molecule belonging to the class of SERDs (Selective Estrogen Receptor Degraders), after at least 2 years of adjuvant endocrine therapy in ER+/HER2- breast cancer at intermediate or high risk of recurrence.
Catanzaro – AOU Renato Dulbecco – Presidio Mater Domini
Principal Investigator: Prof. Pierfrancesco Tassone
For information about enrollment, contact: clinicaltrials.oncology@unicz.it (Tel: +39 0961-3647921)

 

DYNASTY-Breast02 – “A Study of DB-1303/BNT323 vs Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer”

This study evaluates the role of the DB-1303/BNT323 molecule in hormone receptor-positive, HER2-low breast cancer (HER2 immunohistochemistry 1+ or 2+ with negative FISH) in patients who have progressed after two prior lines of hormone therapy or within six months of combined hormone therapy with a CDK4/6 inhibitor. It compares DB-1303/BNT323 to single-agent chemotherapy (capecitabine, paclitaxel, or nab-paclitaxel).
Catanzaro – AOU Renato Dulbecco – Presidio Mater Domini
Principal Investigator: Prof. Pierfrancesco Tassone
For information about enrollment, contact: clinicaltrials.oncology@unicz.it (Tel: +39 0961-3647921)